title: QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
abstract: OBJECTIVE
  To determine whether QRS duration predicts sudden cardiac death (SCD) in patients with left ventricular hypertrophy and treated hypertension.
  
  
  RESULTS
  Over 4.8 +/- 0.9 years follow-up of 9193 hypertensive patients with electrocardiographic evidence of LVH who were treated with atenolol- or losartan-based regimens, 178 patients (1.9%) suffered SCD. In multivariable analysis including randomized treatment, changing blood pressure over time, and baseline differences between patients with and without SCD, QRS duration was independently predictive of SCD (HR per 10 ms increase = 1.22, P < 0.001). Baseline QRS duration remained a significant predictor of SCD even after controlling for the presence or absence of left bundle branch block (HR = 1.17, P = 0.001) and for changes in ECG LVH severity over the course of the study (HR = 1.16, P = 0.017).
  
  
  CONCLUSIONS
  In the setting of aggressive antihypertensive therapy, prolonged QRS duration identifies hypertensive patients at higher risk for SCD, even after controlling for left bundle branch block, other known risk factors for SCD, and changes in blood pressure and severity of left ventricular hypertrophy.
authors.affiliation: Division of Cardiology, Ochsner Clinic Foundation, New Orleans, LA, USA.
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Morin
authors.forename: Lasse
authors.initials: L
authors.lastname: Oikarinen
authors.forename: Matti
authors.initials: M
authors.lastname: Viitasalo
authors.forename: Lauri
authors.initials: L
authors.lastname: Toivonen
authors.forename: Markku S
authors.initials: MS
authors.lastname: Nieminen
authors.forename: Sverre E
authors.initials: SE
authors.lastname: Kjeldsen
authors.forename: Björn
authors.initials: B
authors.lastname: Dahlöf
authors.forename: Majnu
authors.initials: M
authors.lastname: John
authors.forename: Richard B
authors.initials: RB
authors.lastname: Devereux
authors.forename: Peter M
authors.initials: PM
authors.lastname: Okin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001262:Atenolol / Q000627:therapeutic use; D002037:Bundle-Branch Block / Q000150:complications* / Q000503:physiopathology; D016757:Death, Sudden, Cardiac / Q000209:etiology* / Q000517:prevention & control; D004562:Electrocardiography; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
chemical_list: D000959:Antihypertensive Agents; D001262:Atenolol; D019808:Losartan